Tenofovir disoproxil fumarate for the treatment of HIV infection

• SCHAMBELAN M, BENSON CA, CARRA etal.: Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society USA panel. J. Acquir. Immune Defic. Syndr. (2002) 3:257-275.
   Google Scholar
• BARBARO G: Metabolic and cardiovascular complications of highly active antiretroviral therapy for HIV infection. Curr. HIV Res. (2006) 4:79-85.
   PubMed Web of Science ®Google Scholar
• GALLANT JE: Antiretroviral drug resistance and resistance testing. Top. HIV Med. (2005) 13:138-142.
   PubMedGoogle Scholar
• MOORE RD, KERULY JC, GEBO KA etal.: An improvement in virologic response to highly active antiretroviral therapy in clinical practice from 1996 through 2002. J. Acquir. Immune Defic. Syndr. (2005) 39:195-198.
   PubMed Web of Science ®Google Scholar
• FINZI D, BLANKSON J, SILICIANO JD etal.: Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat. Med. (1999) 5:512-517.
   PubMed Web of Science ®Google Scholar
• BARDITCH-CROVO P, DEEKS SG, COLLIER A etal.: Phase I/II trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults. Antimicrob. Agents Chemother. (2001) 45:2733-2739.
   PubMed Web of Science ®Google Scholar
• LOUIE M, HOGAN C, HURLEY A etal.: Determining the antiviral activity of tenofovir disoproxil fumarate in treatment-nave chronically HIV-1-infected individuals. AIDS (2003) 17:1151-1156.
   PubMed Web of Science ®Google Scholar
• WAINBERG MA, MILLER MD, QUANY etal.: Invitro selection and characterization of HIV-1 with reduced susceptibility to PMPA. Antiviral Ther. (1999) 4:87-94.
   PubMed Web of Science ®Google Scholar
• KEARNEY BP, FLAHERTY JF, SAYRE JR etal.: Effect of formulation and food on the pharmacokinetics of tenofovir DF (Abstract3). 2nd International Workshop on Clinical Pharmacology of HIV Therapy. Noordwijk, The Netherlands (2001).
   Google Scholar
• HAWKINS T, VEIKLEY W, ST CLAIRE RL etal.: Intracellular pharmacokinetics of tenofovir diphosphate, carbovir triphosphate, and lamivudine triphosphate in patients receiving triple-nucleoside regimens. J. Acquir. Immune Defic. Syndr. (2005) 39:406-411.
   PubMed Web of Science ®Google Scholar
• BLANCHARD JN, WOHLFEILER M, CANAS A etal.: Pancreatitis with didanosine and tenofovir disoproxil fumarate. Clin. Infect. Dis. (2003) 37:e57-e62.
   PubMed Web of Science ®Google Scholar
• KARRER U, LEDERGERBER B, FURRER H etal.: Dose-dependent influence of didanosine on immune recovery in HIV-infected patients treated with tenofovir. AIDS (2005) 19:1987-1994.
   PubMed Web of Science ®Google Scholar
• NEGREDO E, BONJOCH A, PAREDESR, PUIG J, CLOTET B: Compromised immunologic recovery in treatment-experienced patients with HIV infection receiving both tenofovir disoproxil fumarate and didanosine in the TORO studies. Clin. Infect. Dis. (2005) 41:901-905.
   PubMed Web of Science ®Google Scholar
• BARRIOS A, RENDN A, NEGREDO E etal.: Paradoxical CD4+ T-cell decline in HIV-infected patients with complete virus suppression taking tenofovir and didanosine. AIDS (2005) 19:569-575.
   PubMed Web of Science ®Google Scholar
• RAY AS, OLSON L, FRIDLAND A: Role of purine nucleoside phosphorylase in interactions between 2,3-dideoxyinosine and allopurinol, ganciclovir, or tenofovir. Antimicrob. Agents Chemother. (2004) 48:1089-1095.
   PubMed Web of Science ®Google Scholar
• KEARNEY BP, SAYRE JR, FLAHERTYetal.: Drugdrug and drugfood interactions between tenofovir disoproxil fumarate and didanosine. J. Clin. Pharmacol. (2005) 45:1360-1367.
   PubMed Web of Science ®Google Scholar
• MAITLAND D, MOYLE G, HAND J etal.: Early virologic failure in HIV-1 infected subjects on didanosine/tenofovir/efavirenz: 12-week results from a randomized trial. AIDS (2005) 19:1183-1188.
   PubMed Web of Science ®Google Scholar
• TORTI C, QUIROS-ROLDON E, REGAZZI M etal.: Early virological failure after tenofovir + didanosine + efavirenz combination in HIV-positive patients upon starting antiretroviral therapy. Antivir Ther. (2005) 10:505-513.
   PubMed Web of Science ®Google Scholar
• VAN LUNZEN J, SCHEWE K, KUHLMANN B etal.: High rate of virological failure during once daily therapy with tenofovir + didanosine 250 mg + efavirenz in antiretroviral-nave patients results of the 12-week interim analysis of the TEDDI trial [Abstract TuPp0306]. Program and abstracts of the 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment. Rio de Janeiro, Brazil (2005).
   Google Scholar
• Viread (tenofovir disoproxil fumarate) prescribing information. Gilead Sciences, Foster City, CA, USA (2005).
   Google Scholar
• TABURET AM, PIKETTY C, CHAZALLON C etal.: Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother. (2004) 48:2091-2096.
   PubMed Web of Science ®Google Scholar
• JOHNSON M, DEJESUS E, GRINSZTEIN B etal.: Long-term efficacy and durability of atazanavir (ATV) with ritonavir (RTV) or saquinavir (SQV) versus lopinavir/ritonavir (LPV/RTV) in HIV-infected patients with multiple virologic failures: 96-week results from a randomized, open-label trial, BMS AI424045 [Abstract PL 14.4]. 7th International Congress on Drug Therapy in HIV Infection. Glasgow, UK (2004).
   Google Scholar
• Reyataz (atazanavir) prescribing information. Bristol-Myers Squibb, Princeton, NJ, USA (2006).
   Google Scholar
• GALLANT J, PARISH M, KERULY J, MOORE R: Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse transcriptase inhibitor treatment. Clin. Infect. Dis. (2005) 40:1194-1198.
   PubMed Web of Science ®Google Scholar
• MOLINA JM, WILKIN A, DOMINGO P etal.: Once-daily versus twice-daily lopinavir/ritonavir in antiretroviral-naive patients: 96-week results. [Abstract WePe12.3C12]. 3rd IAS Conference on HIV Pathogenesis and Treatment. Rio de Janeiro, Brazil (2005).
   Google Scholar
• GALLANT JE, STASZEWSKI S, POZNIAK AL etal.: Efficacy and safety of tenofovir DF versus stavudine when used in combination with lamivudine and efavirenz in antiretroviral nave patients: a 3-year randomized trial. JAMA (2004) 292:191-201.
   PubMed Web of Science ®Google Scholar
• GALLANT JE, DEJESUS E, ARRIBAS JR etal.: Tenofovir DF, emtricitabine and efavirenz versus zidovudine, lamivudine and efavirenz for HIV. N. Engl. J. Med. (2006) 354:251-260.
   PubMed Web of Science ®Google Scholar
• GALLANT JE, RODRIGUEZ AE, WEINBERG WG etal.: Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects. J. Infect. Dis. (2005) 192:1921-1930.
   PubMed Web of Science ®Google Scholar
• KHANLOU H, YEH V, GUYER B etal.: Early virologic failure in a pilot study evaluating the efficacy of therapy containing once-daily abacavir, lamivudine, and tenofovir DF in treatment-naive HIV-infected patients. AIDS Patient Care STDS. (2005) 19:135-140.
   PubMed Web of Science ®Google Scholar
• DELAUNAY C, BRUN-VEZINET F, LANDMAN R etal.: Comparative selection of the K65R and M184V/I mutations in human immunodeficiency virus type 1-infected patients enrolled in a trial of first-line triple-nucleoside analog therapy (Tonus IMEA 021). J. Virol. (2005) 79:9572-9578.
   PubMed Web of Science ®Google Scholar
• JEMSEK G, HUTCHERSON P, HARPERE: Poor virologic responses and early emergence of resistance in treatment naive, HIV-infected patients receiving a once daily triple nucleoside regimen of didanosine, lamivudine, and tenofovir DF [Abstract 51]. 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, USA (2004).
   Google Scholar
• PODZAMCZER D, FERRER E, GATELLJM etal.: Early virological failure and occurrence of resistance in nave patients receiving tenofovir, didanosine and efavirenz. Antivir. Ther. (2004) 9:S172.
   Google Scholar
• KURITZKES DR: Less than the sum of its parts: failure of a tenofovir-abacavir-lamivudine triple-nucleoside regimen. J. Infect. Dis. (2005) 192:1867-1868.
   PubMed Web of Science ®Google Scholar
• SQUIRES K, POZNIAK AL, PIERONE G etal.: Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection: a randomized trial. Ann. Intern. Med. (2003) 139:313-320.
   PubMed Web of Science ®Google Scholar
• MCCOLL DJ, MARGOT NA, WULFSOHN M etal.: Patterns of resistance emerging in HIV-1 from antiretroviral-experienced patients undergoing intensification therapy with tenofovir disoproxil fumarate. J. Acquir. Immune Defic. Syndr. (2004) 37:1340-1350.
   PubMed Web of Science ®Google Scholar
• MARGOT NA, ZHONG L, WULFSOHN M, CHENG AK, MILLERMD: Probability and durability of achieving < 50 copies/ml of HIV RNA by treatment intensification with tenofovir DF (TDF) [Abstract H1077]. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, CA, USA (2002).
   Google Scholar
• MILLER MD, MARGOT N, LU B etal.: Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients. J. Infect. Dis. (2004) 189:837-846.
   PubMed Web of Science ®Google Scholar
• WHITE KL, MARGOT NA, WRIN T etal.: Molecular mechanisms of resistance to human immunodeficiency virus type 1 with reverse transcriptase mutations K65R and K65R + M184V and their effects on enzyme function and viral replication capacity. Antimicrob. Agents Chemother. (2002) 46:3437-3446.
   PubMed Web of Science ®Google Scholar
• BAE A, WALTERS J, MARGOT N etal.: Pre-existing L74V is a risk factor for virologic non-response and development of K65R in patients receiving tenofovir DF [Abstract 158]. 8th International HIV Drug Resistance Workshop. Tenerife, Canary Islands, Spain (2004).
   Google Scholar
• SORIANO V, PUOTI M, BONACINI M etal.: Care of patients with chronic hepatitis B and HIV co-infection: recommendations from an HIV-HBV International Panel. AIDS (2005) 19:221-240.
   PubMed Web of Science ®Google Scholar
• DORE GJ, COOPER DA, POZNIAK AL etal.: Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus. J. Infect. Dis. (2004) 189:1185-1192.
   PubMed Web of Science ®Google Scholar
• OGEDEBE AO, THOMAS DL, DIEHLAM: Hyperlactataemia syndrome associated with HIV therapy. Lancet (2003) 3:323-337.
   PubMed Web of Science ®Google Scholar
• BIRKUS G, HITCHCOCK MJM, CIHLAR T: Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside analog transcriptase inhibitors. Antimicrob. Agents Chemother. (2002) 46:716-723.
   PubMed Web of Science ®Google Scholar
• FENG JY, MURAKAMI E, ZORCA SM etal.: Relationship between antiviral activity and host toxicity: comparison of the incorporation efficiencies of 2,3-dideoxy-5-fluoro-3-thiacytidine-triphosphate analogs by human immunodeficiency virus type 1 reverse transcriptase and human mitochondrial DNA polymerase. Antimicrob. Agents Chemother. (2004) 48:1300-1306.
   PubMed Web of Science ®Google Scholar
• BIRKUS G, HAJEK M, KRAMATA P etal.: Tenofovir diphosphate is a poor substrate and a weak inhibitor of rat DNA polymerases , , and . Antimicrob. Agents Chemother. (2002) 46:1610-1613.
   PubMed Web of Science ®Google Scholar
• BIESECKER G, KARIMI S, DESJARDINS J etal.: Evaluation of mitochondrial DNA content and enzyme levels in tenofovir DF-treated rats, rhesus monkeys, and woodchucs. Antiviral Res. (2003) 58:217-225.
   PubMed Web of Science ®Google Scholar
• RIBERA E, PARADINEIRO J, SAULEDAS etal.: Improvement of subcutaneous fat, lipid profile, and parameters of mitochondrial toxicity in patients with peripheral lipoatrophy when stavudine is switched to tenofovir [Abstract 860]. The LIPOTEST study. 12th Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA (2005).
   Google Scholar
• MILINKOVIC A, LOPEZ S, VIDAL S etal.: A randomized open study comparing the effect of reducing stavudine dose versus switching to tenofovir on mitochondrial function, metabolic parameters, and subcutaneous fat in HIV-infected patients receiving antiretroviral therapy containing stavudine [Abstract 857]. 12th Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA (2005).
   Google Scholar
• MOYLE G, SABIN C, CARTLEDGE J etal.: Factors associated with limb fat recovery in a prospective randomized comparative study of thymidine replacement with either tenofovir DF or abacavir in persons with clinical lipoatrophy [Abstract PE9.3/2]. 10th European AIDS Conference. Dublin, Ireland (2005).
   Google Scholar
• MADRUGA JVR etal.: Impact of switching off d4T on lipids and limb fat [Abstract TuPe2.2b12]. 3rd International AIDS Society Conference. Rio de Janeiro, Brazil (2005).
   Google Scholar
• DA SILVA B, ALBRECHT M, BENSONC etal.: Improved metabolic profile with replacement of stavudine by tenofovir DF after 6 years of a lopinavir/ritonavir-based regimen. [Abstract 62]. 7th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. Dublin, Ireland. Antivir.Ther. (2005) 10:L38.
   Google Scholar
• PEYRIERE H, REYNES J, ROUANET I etal.: Renal tubular dysfunction associated with tenofovir therapy: report of 7 cases. J. Acquir. Immune Defic. Syndr. (2004) 35:269-273.
   PubMed Web of Science ®Google Scholar
• BLICK G, GRIEGER-ZANLUNGO, GARTON T, HATTON E, LOPEZ RJ: Tenofovir may cause severe hypophosphatemia in HIV/AIDS patients with prior adefovir-induced renal tubular acidosis. [Abstract 718]. 10th Conference on Retroviruses and Opportunistic Infections. Boston, USA (2003).
   Google Scholar
• IZZEDINE H, HULOT JS, VITTECOQD etal.: Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-nave HIV-1-infected patients. Data from a double-blind randomized active-controlled multicentre study. Nephrol. Dial. Transplant. (2005) 20:743-746.
   PubMed Web of Science ®Google Scholar
• KARRAS A, LAFAURIE M, FURCO A etal.: Tenofovir-related nephrotoxicity in human immunodeficiency virus-infected patients: three cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidus. Clin. Infect. Dis. (2003) 36:1070-1073.
   PubMed Web of Science ®Google Scholar
• RIFKIN BS, PERAZELLA MA: Tenofovir-associated nephrotoxicity: Fanconi syndrome and renal failure. Am. J. Med. (2004) 117:282-284.
   PubMed Web of Science ®Google Scholar
• HANSEN AB, MATHIESEN S, GERSTOFT J: Severe metabolic acidosis and renal failure in an HIV-1 patient receiving tenofovir. Scand J. Infect. Dis. (2004) 36:389-392.
   PubMed Web of Science ®Google Scholar
• BARRIOS A, GARCIA-BENAYAS T, GONZALES-LAHOZ J etal.: Tenofovir-related nephrotoxicity in HIV-infected patients. AIDS (2004) 18:960-963.
   PubMed Web of Science ®Google Scholar
• JAMES CW, STEINHAUS MC, SZABO S etal.: Tenofovir-related nephrotoxicity: case report and review of the literature. Pharmacotherapy (2004) 24:415-418.
   PubMed Web of Science ®Google Scholar
• ZIMMERMANN A, PIZZOFERRATO T, BEDFORD J etal.: Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions. Clin. Infect. Dis. (2006) 42:283-290.
   PubMed Web of Science ®Google Scholar
• GALLANT JE, PARISH MA, KERULY JC etal.: Tenofovir and changes in renal function [letter reply]. Clin. Infect. Dis. (2005) 41:571.
   PubMed Web of Science ®Google Scholar
• ANTONIOU T, RABOUD J, CHIRHINS etal.: Incidence of and risk factors for tenofovir-induced nephrotoxicity: a retrospective cohort study. HIV Med. (2005) 6:284-290.
   PubMed Web of Science ®Google Scholar
• FDA Antiviral Drug Products Advisory Committee Meeting, Tenofovir Disoproxil Fumarate. Silver Spring, Maryland, USA (2001).
   Google Scholar
• POWDERLY W, COHEN C, GALLANTJE etal.: Similar incidence of osteopenia and osteoporosis in ART-nave patients treated with tenofovir DF or stavudine in combination with lamivudine and efavirenz over 144 weeks. [Abstract 823] 12th Conference on Retrovirus and Opportunistic Infections. Boston, USA (2005).
   Google Scholar
• TARANTAL AF, CASTILLO A, EKERTJE, BISCHOFBERGER N, MARTIN RB: Fetal and maternal outcome after administration of tenofovir to gravid rhesus monkeys (Macaca mulatta). J. Acquir. Immune Defic. Syndr. (2002) 29:207.
   PubMed Web of Science ®Google Scholar
• HAZRA R, GAFNI R, MALDARELLI F etal.: Safety, tolerability, clinical responses to tenofovir DF in combination with other antiretrovirals in heavily treatment-experienced HIV-infected children: data through 48 weeks [Abstract 928] 11th Conference on Retrovirus and Opportunistic Infections. San Francisco, USA (2004).
   Google Scholar
• GIACOMET V, MORA S, MARTELLI L etal.: A 12-month treatment with tenofovir does not impair bone mineral accrual in HIV-infected children. J. Acquir. Immune Defic. Syndr. (2005) 40:448-450.
   PubMed Web of Science ®Google Scholar
• MATHIAS A, PLUMMER A, SKILLINGTON J et al.: Bioequivalence of efavirenz/emtricitabine/tenofovir DF single tablet formation. 7th International Workshop on Clinical Pharmacology of HIV Therapy. Lisbon, Portugal (2006).
   Google Scholar
• GUPTA SK, EUSTACE JA, WINSTONJA etal.: Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin. Infect. Dis. (2005) 40:1559-1585.
   PubMed Web of Science ®Google Scholar
• TSAI C-C, FOLLIS KE, SABO A etal.: Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl) adenine. Science (1995) 270:1197-1199.
   PubMed Web of Science ®Google Scholar
• KEARNEY BP, LIAW S, YALE K etal.: Pharmacokinetics following single dose administration of tenofovir DF in subjects with renal impairment. [Abstract P4]. 6th International Congress on Drug Therapy in HIV Infection. Glasgow, UK (2002).
   Google Scholar
• WHITE KL, MARGOT NA, WRIN T, PETROPOULOS CH, MILLER MD, NAEGER LK: Molecular mechanisms of resistance to human immunodeficiency virus type I with reverse transcriptase mutations K65R and K65R + M184V and their effects on enzyme function and viral replication capacity. Antimicrob. Agents Chemother. (2002) 46:3437-3446.
   PubMed Web of Science ®Google Scholar
• GARCIA-LERMA G, MACINNES H, NIDTHA S etal.: Invitro selection of the T215Y and K65R mutations by stavudine and demonstration of high-level resistance to stavudine. Antiviral Ther. (2002) 7:S28.
   Google Scholar
• MILLER MD, MARGOT NA, MCCOLLDJ, COAKLEY DF, CHENGAK: Final 144 week resistance analysis for treatment-nave patients taking tenofovir DF (TDF) or stavudine (d4T) in combination with lamivudine (3TC) and efavirenz (EFV). [Abstract 5757]. XV International AIDS Conference. Bangkok, Thailand (2005).
   Google Scholar
• MCCOLL DJ, MARGOT NA, CHENGAK, MILLER MD: Development of K65R versus thymidine analog-association mutations (TAMs) in antiretroviral-treated patients. [Abstract P206]. 6th International Congress on Drug Therapy in HIV Infection. Glasgow, UK (2002).
   Google Scholar
• NAEGER LK, MARGOT NA, MILLERMD: ATP-dependent removal of nucleoside reverse transcriptase inhibitors by human immunodeficiency virus type I reverse transcriptase. Antimicrob. Agents Chemother. (2002) 46:2179-2184.
   PubMed Web of Science ®Google Scholar
• MARGOT NA, ISAACSON E, MCGOWAN I etal.: Extended treatment with tenofovir disoproxil fumarate in treatment-experienced HIV-1-infected patients: genotypic, phenotypic, and rebound analyses. J. Acquir. Immune Defic. Syndr. (2003) 33:15-21.
   PubMed Web of Science ®Google Scholar
• MILLER MD, MARGOT N, LU B, ZHONG L, CHEN SS, CHENG A, WULFSOHN M: Genotypic and phenotypic predictors of the magnitude of response to tenofovir DF in antiretroviral-experienced patients. J. Infect. Dis. (2002) 189:837-846.
   Web of Science ®Google Scholar

Websites

• http://www.unaids.org AIDS Epidemic Update December (2005). UNAIDS publication CP125.
   Google Scholar
• http://www.hivatis.org Panel on Clinical Practices for Treatment of HIV Infection, Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents (2006). HIV/AIDS Treatment Information Service Website.
   Google Scholar